Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats

Copyright © 2017. Published by Elsevier Inc.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 184(2017) vom: 10. Nov., Seite 77-81
Auteur principal: Gertel, Smadar (Auteur)
Autres auteurs: Mahagna, Hussein, Karmon, Gidi, Watad, Abdulla, Amital, Howard
Format: Article en ligne
Langue:English
Publié: 2017
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, Non-U.S. Gov't Adjuvant induced arthritis (AIA) Pro-inflammatory cytokine IL-1β Th1 cells Tofacitinib Antirheumatic Agents IL1B protein, rat Interleukin-1beta Piperidines plus... Protein Kinase Inhibitors Pyrimidines Pyrroles RNA, Messenger Interferon-gamma 82115-62-6 tofacitinib 87LA6FU830 C-Reactive Protein 9007-41-4 Methotrexate YL5FZ2Y5U1
Description
Résumé:Copyright © 2017. Published by Elsevier Inc.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by pronounced inflammation and leukocyte infiltration in affected joints. Tofacitinib is new agent, a selective inhibitor of Janus kinase (JAK) signaling pathways mediated by JAK1 and JAK3 and inhibits the key transcription factors STAT1 and STAT3. We investigated the action mechanisms of tofacitinib in rats with adjuvant-induced-arthritis (AIA). AIA-rats were treated orally with tofacitinib or with methotrexate. Arthritis severity and serum C-reactive protein (CRP) levels were evaluated, splenic cells were examined by flow cytometry and cytokines were analyzed by real-time PCR. Tofacitinib markedly reduced the clinical status of treated rats in comparison to control group. Reduced joints inflammation and down-regulated serum CRP levels reflected the clinical manifestations of the treated rats. Tofacitinib down-regulated significantly the frequency of CD4+IFN-γ+ T cells and reduced IL-1β mRNA expression levels in the spleen of the treated rats. These results show that tofacitinib attenuated arthritis severity, modified splenic populations and cytokine imbalance
Description:Date Completed 16.11.2017
Date Revised 06.02.2018
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2017.04.015